Original Research

Published on 23 Feb 2023

Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis

in Cancer Molecular Targets and Therapeutics

Andrea Caddeo
Marina Serra
Francesca Sedda
Andrea Bacci
Clementina Manera
Simona Rapposelli
Amedeo Columbano
Andrea Perra
Marta Anna Kowalik

Frontiers in Oncology

doi 10.3389/fonc.2023.1127517

3,956 views
4 citations

Original Research

Published on 23 Feb 2023

Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma

in Cancer Molecular Targets and Therapeutics

Shuangwu Dai
Xinxin Shao
Qingzhu Wei
Shaohua Du
Changhe Hou
Haomiao Li
Dadi Jin

Frontiers in Oncology

doi 10.3389/fonc.2023.819357

1,831 views
3 citations

Original Research

Published on 23 Feb 2023

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)

in Cancer Molecular Targets and Therapeutics

Xiao-Dong Jiao
Bao-Dong Qin
Zhan Wang
Ke Liu
Ying Wu
Yan Ling
Wen-Xing Qin
Miao-Miao Wang
Ling-Yan Yuan
Savio George Barreto

Frontiers in Oncology

doi 10.3389/fonc.2023.860711

3,293 views
2 citations

Case Report

Published on 22 Feb 2023

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

in Cancer Molecular Targets and Therapeutics

Yun Zhao
Cuiyun Su
Lina Shi
Wenqi Luo
Zhen Liu
Chuqiao Liang
Huilin Wang
Ruiling Ning
Qitao Yu
Wei Jiang

Frontiers in Oncology

doi 10.3389/fonc.2023.1126325

2,277 views
2 citations

Original Research

Published on 22 Feb 2023

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study

in Cancer Molecular Targets and Therapeutics

Zhiyong Liu
Xin Wang
Jiaqiang Wang
Peng Zhang
Chao Li
Bangmin Wang
Songtao Gao
Oufei Liu
Weitao Yao

Frontiers in Oncology

doi 10.3389/fonc.2023.1124517

1,520 views
5 citations

Mini Review

Published on 20 Feb 2023

ARID1A in cancer: Friend or foe?

in Cancer Molecular Targets and Therapeutics

Beatrice Fontana
Giulia Gallerani
Irene Salamon
Ilaria Pace
Roberta Roncarati
Manuela Ferracin

Frontiers in Oncology

doi 10.3389/fonc.2023.1136248

9,231 views
10 citations

Review

Published on 16 Feb 2023

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer

in Cancer Molecular Targets and Therapeutics

Yinghao Zhao
Shengnan Jia
Kun Zhang
Lian Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1064616

2,993 views
3 citations

Original Research

Published on 16 Feb 2023

Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma

in Cancer Molecular Targets and Therapeutics

Kun Zheng
Yushan Hou
Yiming Zhang
Fei Wang
Aihua Sun
Dong Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1111570

2,788 views
2 citations

Case Report

Published on 13 Feb 2023

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report

in Cancer Molecular Targets and Therapeutics

Junhui Wang
Huijuan He
Wansu Xu
Jianxin Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1010871

1,422 views
2 citations

Original Research

Published on 10 Feb 2023

High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification

in Cancer Molecular Targets and Therapeutics

Xiaohong Jiang
Fuxing Tang
Junlei Zhang
Mingwei He
Tianyu Xie
Haijun Tang
Jianhong Liu
Kai Luo
Shenglin Lu
Yun Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.991483

2,789 views

Clinical Trial

Published on 09 Feb 2023

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

in Cancer Molecular Targets and Therapeutics

Paolo A. Ascierto
Eleonora Cioli
Vanna Chiarion-Sileni
Pietro Quaglino
Francesco Spagnolo
Massimo Guidoboni
Michele Del Vecchio
Ketty Peris
Paola Queirolo
Luisa Fioretto

Frontiers in Oncology

doi 10.3389/fonc.2023.1107307

2,562 views
1 citation

Case Report

Published on 09 Feb 2023

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

in Cancer Molecular Targets and Therapeutics

Elise F. Nassif
Cissimol P. Joseph
Rossana Lazcano
Jocelyn T. Joseph
Prapassorn Thirasastr
Alexander J. Lazar
Neeta Somaiah

Frontiers in Oncology

doi 10.3389/fonc.2023.1046442

1,543 views
1 citation

Original Research

Published on 09 Feb 2023

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers

in Cancer Molecular Targets and Therapeutics

Qingyi Hu
Jiaoshun Chen
Wen Yang
Ming Xu
Jun Zhou
Jie Tan
Tao Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.990551

4,511 views
7 citations

Original Research

Published on 08 Feb 2023

CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma

in Cancer Molecular Targets and Therapeutics

Shen Xue
Xiao-min Su
Li-na Ke
Yu-gang Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1077780

3,007 views
7 citations

Original Research

Published on 08 Feb 2023

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

in Cancer Molecular Targets and Therapeutics

Daniel J. Sisler
Trista K. Hinz
Anh T. Le
Emily K. Kleczko
Raphael A. Nemenoff
Lynn E. Heasley

Frontiers in Oncology

doi 10.3389/fonc.2023.1094123

5,213 views
2 citations

Original Research

Published on 06 Feb 2023

A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Bingqian Hu
Alphonse Houssou Hounye
Zheng Wang
Min Qi
Jianglin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1108128

2,755 views
1 citation

Navigation group

Articles

Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis

Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study

ARID1A in cancer: Friend or foe?

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer

Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report

High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers

CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis